RE:RE:RE:RE:articleThere it is M80 : Our model projects peak U.S. MCNA sales by 2025 of US$188M, obviously predicated on FDA approval, and global MCNA-derived revenue that year, including rest-of-world royalty revenue from Ipsen of US$254M. --- https://www.thelifesciencesreport.com/pub/na/16869?utm_source=delivra&utm_medium=email&utm_campaign=TLSR+Final+1%2D13%2D16
Please check my question to you about primary endpoint set by FDA at 40% to 60% and actual disease free result at 25%, any comment?